| 000 | 01601 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517071522.0 | ||
| 264 | 0 | _c20161028 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1939-1676 | ||
| 024 | 7 |
_a10.1111/jvim.13817 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRiederer, A | |
| 245 | 0 | 0 |
_aEffect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus. _h[electronic resource] |
| 260 |
_bJournal of veterinary internal medicine _c |
||
| 300 |
_a92-100 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAnimal Feed _xanalysis |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBlood Glucose |
| 650 | 0 | 4 |
_aCat Diseases _xdrug therapy |
| 650 | 0 | 4 | _aCats |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xdrug therapy |
| 650 | 0 | 4 |
_aDiet _xveterinary |
| 650 | 0 | 4 |
_aDietary Carbohydrates _xpharmacology |
| 650 | 0 | 4 | _aExenatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHypoglycemia _xchemically induced |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aInsulin Glargine _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPeptides _xadverse effects |
| 650 | 0 | 4 |
_aVenoms _xadverse effects |
| 700 | 1 | _aZini, E | |
| 700 | 1 | _aSalesov, E | |
| 700 | 1 | _aFracassi, F | |
| 700 | 1 | _aPadrutt, I | |
| 700 | 1 | _aMacha, K | |
| 700 | 1 | _aStöckle, T M | |
| 700 | 1 | _aLutz, T A | |
| 700 | 1 | _aReusch, C E | |
| 773 | 0 |
_tJournal of veterinary internal medicine _gvol. 30 _gno. 1 _gp. 92-100 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jvim.13817 _zAvailable from publisher's website |
| 999 |
_c25572236 _d25572236 |
||